Basic Information
| LncRNA/CircRNA Name | MIR4435-2HG |
| Synonyms | NA |
| Region | GRCh38_2:111036776-111523376 |
| Ensemble | ENSG00000172965 |
| Refseq | NR_015395 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown, RIP |
| Sample | lung cancer tissues, cell lines(A549, H1770,H596, H1975, H1650 and H1299) |
| Expression Pattern | up-regulated |
| Function Description | MIR4435-2HG was highly expressed in lung cancer tissues and correlated with histological grades and lymph node metastasis. Kaplan-Meier analysis ofthe 52 patients with lung cancer revealed that high MIR4435-2HG expression in lung cancer tissues was significantly corre-lated with a reduction in overall survival. Phenotypic analysis indicated that MIR4435-2HG knockdown inhibited lung cancer cell proliferation and invasion in vitro and in vivo. Notably, MIR4435-2HG knockdown suppressed the EMT (epithelial-mesenchymal transition) process and cancer stem cell traits of lung cancer cells. Mechanistically, MIR4435-2HG knockdown decreased the transactivation of ?-catenin. MIR4435-2HG interacted with ?-catenin and thus prevented its degradation by the proteasome system. |
| Pubmed ID | 29872866 |
| Year | 2018 |
| Title | The lncRNA MIR4435-2HG Promotes Lung Cancer Progression by Activating ?-Catenin Signalling |
External Links
| Links for MIR4435-2HG | GenBank HGNC NONCODE |
| Links for lung cancer | OMIM COSMIC |